Prognosis for Lymphomas

Prognostic indices have been developed for the indolent and aggressive lymphomas. The International Prognostic Index (IPI) (65) is utilized to evaluate a patient's risk status for the aggressive lymphomas. The Follicular Lymphoma IPI (FLIPI) (66) is similarly utilized for the indolent follicular lymphomas. Using the IPI or FLIPI to determine therapy is the subject of ongoing clinical trials. The IPI and FLIPI criteria are shown in Tables 3 and 4, respectively. It is important to note that the IPI was validated using the conventional CHOP or similar chemotherapy regimen prior to the introduction of the widely used monoclonal antibody rituximab. Moreover, there is a lack of studies applying these prognostic indices to primary head and neck extranodal lymphomas.

0 0

Post a comment